Abris Heisz

Abris Heisz

Auto-generated profile, based on publicly available information

Abris Heisz

VERDI Solutions GmbH, 1070 Vienna, Austria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2025 in Exploration of Immunology
Verified
Journal Article
Open access
PDF file
JLJulianna Lisziewicz
Julianna Lisziewicz
ASAndras Szasz
Andras Szasz
TKTamas Kos
Tamas Kos
AHAbris Heisz
Abris Heisz
ALFREDO MINGUELA PURASALFREDO MINGUELA PURAS
ALFREDO MINGUELA PURAS
BPBartolome Garcia Perez
Bartolome Garcia Perez
T cell-based immunotherapies increasingly include personalized neoantigen vaccines that target tumor-specific mutations. However, despite their promise, current neoantigen vaccines show limited and unpredictable clinical benefit, with T cell responses observed in only a subset of patients. To overcome these limitations, we developed the VERDI (Vaccine Epitopes Ranked by Digital Intelligence) System—a cloud-based computational platform that integrates a patient’s human leukocyte antigen (HLA) class I and II genotype with selected tumor-associated antigens (TAAs), including cancer-testis antigens (CTAs), to identify peptides with high predicted immunogenicity and low risk of immune-related adverse events (irAEs). Using the VERDI System, we designed ten personalized peptide vaccines for a patient with metastatic signet ring cell carcinoma (SRCC), a rare and aggressive gastric cancer with limited treatment options. All ten VERDI vaccines were well tolerated and consistently induced tumor-specific T cell responses following a single administration, without the need for checkpoint inhibitors. The patient survived for 15 months—substantially longer than the reported median survival of 5.6 months in metastatic SRCC—highlighting the potential of this individualized, predictive vaccine platform to improve outcomes in advanced cancer.